RA Capital Management is a Boston-based investment firm that pursues evidence-based investing across public and private healthcare, life sciences, and planetary health sectors. The firm supports the growth of innovative companies from seed to later-stage financings, focusing on drugs, medical devices, diagnostics, biotech services, and research tools. RA Capital combines a data-driven research platform, TechAtlas, with a collaborative investment approach and a healthcare incubator, Raven, to help management teams advance ideas from inception through development and commercialization. It frequently co-invests, takes board seats, and participates in follow-on financings, aiming to back ventures that improve patient outcomes and reduce costs. The firm emphasizes US and European opportunities, maintains a multi-stage investment scope, and is headquartered in Boston.

OrbiMed is a global healthcare investment firm focused on supporting the development of therapies, medical devices, diagnostics, and health IT. Established in 1989, it manages a broad investment platform across venture capital, private equity, and public equity, targeting opportunities from early-stage startups to mature companies. The firm backs companies across biopharmaceuticals, biotechnology, life sciences, and digital health, providing financing and strategic resources to accelerate innovation. With a multinational presence and offices in New York, San Francisco, Mumbai, Herzliya, Shanghai, and beyond, OrbiMed pursues a diversified portfolio of healthcare companies worldwide.

Invus is a global investment firm founded in 1985 that builds lasting value by partnering with management teams to transform industries. It employs a flexible, long-term approach, aligning incentives with entrepreneurs and investors, and providing capital and strategic guidance to support growth through cycles. The firm invests directly in companies and makes selective co-investments across sectors including consumer products and services, technology, life sciences, software, agtech, industrials, and education. With a patient mindset and emphasis on backing owner-managers, Invus seeks opportunities where its involvement adds strategic value beyond capital. It maintains offices in New York, London, Paris, and Hong Kong and operates a substantial evergreen capital base to sustain support for portfolio companies over extended horizons.

Vivo Capital is a global healthcare investment firm founded in 1996 and headquartered in Palo Alto, California, with offices in Asia. It operates a multi-strategy platform spanning venture capital, private equity including buyouts, growth equity, and public equity, and invests across biopharmaceuticals, specialty pharmaceuticals, medical devices, diagnostics, and healthcare services. The firm backs hundreds of companies worldwide, with a focus on the United States and China, and maintains a track record of portfolio exits through initial public offerings and mergers and acquisitions. Its team comprises physicians, scientists, entrepreneurs, operating executives, and industry experts who collaborate to build high-quality healthcare companies and advance patient outcomes. Reported assets under management are approximately six billion dollars.

Samsara BioCapital is a biotechnology-focused venture capital firm based in Palo Alto, California, established in 2016. The firm concentrates on funding and supporting biotechnology companies and transformative therapeutics across the United States, leveraging multidisciplinary expertise and strategic partnerships to accelerate clinical and commercial breakthroughs. As a registered investment adviser, Samsara BioCapital combines scientific insight with strategic resources to help entrepreneurs advance innovative medicines.

ARCH Venture Partners is a Chicago-based venture capital firm founded in 1986 that concentrates on science-driven companies, particularly in life sciences, biotechnology and related technologies. It backs early-stage ventures co-founded by scientists and entrepreneurs, and provides strategic guidance, expertise, and a broad network to translate academic and national-lab innovations into commercial products. The firm operates from Chicago and Seattle and has raised more than $3 billion across ten venture funds and invested in more than 150 companies.

New Enterprise Associates is a global venture capital firm founded in 1977 and headquartered in Menlo Park, California. It provides capital and operational support to technology and healthcare companies across stages from seed to IPO, with investments spanning software, consumer technology, medical devices, life sciences, AI, energy technology, and related sectors. The firm collaborates with founders on product development, market expansion, and navigating evolving markets, offering domain expertise alongside funding. With a long-standing track record of portfolio companies achieving IPOs and strategic acquisitions, NEA maintains a global footprint and active involvement in the United States, Asia and other regions, supporting companies throughout their growth lifecycle.

Morningside is a venture capital firm based in the greater Boston area, founded in 1986 as a family office for the Chan family. It makes investments in companies developing novel science and technology across life sciences, digital health, artificial intelligence, materials and general technology, with a long-term, values-driven approach and a focus on ethical company-building. The team comprises investment professionals with deep sector experience, and the firm maintains charitable commitments to education, research and healthcare, supporting institutions such as the Harvard T.H. Chan School of Public Health, UMass Chan Medical School and the MIT Morningside Academy for Design.

Deep Track Capital is a Greenwich, Connecticut-based venture capital firm focused on the biotechnology and life sciences sectors. It invests in public and pre-IPO biotechnology companies and emphasizes partnering with management teams, offering time, expertise, and a broad network in addition to capital. The firm aims to lead transactions, form large syndicates, and participate in rounds led by other qualified investors, providing strategic guidance and resources to portfolio companies.

The European Innovation Council is a European Commission initiative that supports Europe’s deep-tech innovators, researchers, and startups. It funds breakthrough research and technology transfer projects, and delivers equity-like investments through the EIC Fund, as well as prizes and acceleration services to help teams scale. The council also co-invests with private investors in early-stage ventures and places emphasis on high-impact technologies with ESG relevance. Established in 2018 and headquartered in Brussels, it concentrates on deep-tech sectors including defence and dual-use technologies, while promoting international collaboration and market access for awardees. It aims to strengthen Europe’s innovation ecosystem by sharing data, hosting events, publishing insights, and fostering partnerships that accelerate the journey from lab to market.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and based in San Francisco, with offices in Canada and Europe. It invests across the healthcare spectrum, including life sciences, biotechnology, pharmaceuticals and medical devices, at early and later stages. The firm blends deep scientific and operating expertise with investment experience to support company building, often applying a hands-on approach to advancing discoveries from academic origins toward commercial therapies and devices. Through its practice and partnerships, Versant has backed portfolio companies that have achieved acquisitions or public listings, underscoring its track record of translating scientific advances into market outcomes.

Forbion is a global venture capital firm based in Naarden, Netherlands, focused on biotech, life sciences, human health and planetary health, investing in early-stage and growth-stage companies. It provides capital and strategic guidance to portfolio companies across Europe, North America and beyond, and operates a family of funds totaling several billion euros. The firm backs companies in drug development, biotechnology, medical devices and sustainable technologies, with ESG considerations integrated into its investment approach. Its team spans the Netherlands, Germany and the United States, and the firm has notable investments in Azafaros, VectorY and Genomines.

Logos Capital is an investment firm based in San Francisco that focuses on biotechnology. Founded in 2019, the company combines data analytics with scientific and clinical expertise to identify transformative therapies and opportunities in healthcare. Its multidisciplinary team spans biotechnology, medicine, and data science, and it uses a proprietary Logos Analytics platform to model clinical data, informing diligence and investment decisions. Logos Capital seeks long-term value by providing capital and strategic guidance to companies advancing innovative therapies, applying rigorous risk management and comprehensive analysis of clinical, regulatory, operational, and commercial factors. The firm evaluates opportunities across private and public biotechnology companies, aiming to generate meaningful returns through disciplined research and evidence-based investing.

Deerfield Management is a New York–based healthcare investment firm focused on advancing health outcomes through investment, research, and philanthropy. It invests across public and private markets in biotechnology, pharmaceuticals, diagnostics, healthcare services, medical devices, and digital health, using flexible funding models and strategic partnerships to support companies at various stages and to foster innovation. The firm operates an internal research and development engine to accelerate discovery and development, and maintains a philanthropic foundation that funds education, healthcare access, and initiatives to improve health outcomes. Through collaboration with strategic partners and a commitment to data-driven insights, Deerfield Management seeks to advance healthcare technology and services while building a broader, sustainable health ecosystem.

TCG Crossover is a science-driven healthcare investment firm focused on supporting the development of disruptive medicines. It invests in both private and public companies led by entrepreneurs pursuing better treatment options and maintains a portfolio aimed at advancing innovative pharmaceutical solutions. Based in Palo Alto, California, with investment teams in Palo Alto and New York City, the firm targets investments in the United States and Europe, emphasizing healthcare, digital health, and health technology sectors.

Sofinnova Investments is a venture capital firm founded in 1976 and based in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It focuses on seed through early-stage investments and selected later-stage opportunities in life sciences and information technology across the United States and Europe. In life sciences, it backs clinical-stage pharmaceutical products, biotechnology, biopharmaceuticals, therapeutic drugs and medical technology platforms addressing unmet medical needs, with initial investments typically in the low millions and total commitments in the tens of millions; the firm often requires a board seat when leading or co-leading early rounds. In information technology, it supports product-oriented IT, enterprise software, service-provider software and telecommunications infrastructure across development stages. Sofinnova collaborates with entrepreneurs to secure initial funding, build teams, win customers and navigate acquisitions and IPOs, leveraging domain expertise to help portfolio companies scale globally. It does not invest in healthcare services, diagnostics, nutraceuticals or tool-kit ventures.

Atlas Venture is a biotechnology-focused venture capital firm based in Cambridge, Massachusetts, with a long history dating back to 1980. The firm backs early-stage life sciences companies and technology startups, emphasizing seed-led venture creation and lead investing with board representation to help translate breakthrough science into medicines and medical technologies. Atlas partners with life science entrepreneurs across the United States and Europe, supporting companies in biopharmaceuticals, therapeutics, drug discovery platforms, diagnostics, medical devices, and related biotech innovations. The firm combines venture capital expertise with operational insight to build scalable companies, aiming to advance science from discovery to commercialization. Through its incubator and portfolio approach, Atlas has fostered numerous startups and maintains a focus on personalized medicine and next-generation biotech platforms.

SOSV is a global venture capital firm focused on deep tech investments that address human and planetary health, backing seed-to-growth startups and delivering hands-on programs that accelerate product development, customer acquisition, and fundraising. It operates accelerator-like facilities for deep tech founders, including IndieBio in San Francisco and New York (referred to as SOSV SF & NY) and HAX in Newark, offering labs, offices, engineering support, mentorship, and broad access to an investor network. With a large and active portfolio across dozens of countries, SOSV supports hundreds of pre-seed and follow-on investments annually from its New Jersey base and through its global network, emphasizing long-term founder support beyond initial funding and fostering collaboration among portfolio companies and investors.

Sofinnova Partners is an independent venture capital firm based in Paris, France, founded in 1972, focusing on life sciences across biopharmaceuticals, biotech, medical devices, digital medicine and related sectors. It invests from seed to later stages and often acts as a lead or cornerstone investor, typically engaging early in Round A financings and taking a board seat to work closely with entrepreneurs from formation onward. The firm backs start-ups, early-stage companies, corporate spin-offs and occasional turnaround situations, seeking transformative innovations that can improve patient outcomes and contribute to healthcare and sustainability. Its portfolio approach combines active partnership, hands-on governance and long-term collaboration with founders to advance scientific and clinical progress.

Boxer Capital is a biotechnology investment firm that serves as the corporate venture capital arm of Tavistock Group. Based in the United States, the firm invests in public and private biotechnology and life sciences companies across the drug development lifecycle, from early discovery to commercial stage, with a focus on precision medicine and transformative medical advancements. Boxer Capital combines fundamental research with a multidisciplinary analysis of scientific, clinical, regulatory, and commercial factors to translate innovation into opportunity. It pursues opportunities across the full drug lifecycle and provides financial capital and strategic guidance to portfolio companies. The firm notes partnerships with companies such as Mirati Therapeutics and Pandion Therapeutics as examples of its collaborative approach.

EcoR1 Capital is a San Francisco-based investment firm focused on the biotechnology sector. As a venture capital investor and registered investment adviser, it partners with entrepreneurs developing novel medicines and life-saving therapeutics, supporting discovery and development through long-term collaborations. The firm emphasizes a molecular understanding of biology and chemistry to identify promising opportunities with potential patient impact, investing across early-stage and later-stage biotech companies. It backs innovative ventures addressing unmet medical needs and aims to accelerate translational research to bring transformative therapeutics to patients.

Omega Funds is a Boston-based investment firm that focuses on life sciences and healthcare, including biotechnology, digital health, immunology, rare diseases, and oncology, with additional exposure to software-as-a-service. The firm pursues early-stage and venture investments in North America and Western Europe and maintains offices in Boston and Geneva. It operates as a registered investment adviser, offering strategic support to portfolio companies to advance medical products to patients.

SR One Capital Management is the corporate venture capital arm of GlaxoSmithKline. It is a transatlantic life sciences venture capital firm that invests globally in emerging biotechnology, healthcare, and related scientific ventures pursuing innovations with potential to significantly improve medical care. Founded in 1985 and based in Redwood City, California, the firm maintains a presence in major biotech hubs across the United States and London, providing geographic reach and sector expertise to portfolio companies. It employs a back-and-build approach, partnering with founders to translate scientific breakthroughs into new medicines, and has invested around $800 million in more than 180 companies.

HBM Healthcare Investments is a Switzerland-based investment firm focused on globally diversified investments in private and public healthcare companies. Founded in 2001 and headquartered in Zug, it concentrates on sectors including human medicine, biotechnology, medical technology and diagnostics, maintaining a portfolio across private holdings, public equities and funds. The company seeks exposure to healthcare growth drivers such as medical innovation, rising access to care and demographic trends, and operates with a global reach to identify opportunities across mature and emerging companies.

Mission BioCapital is a life science venture capital firm that provides early-stage capital and hands-on support to founders from concept through clinical development. Its leadership team has a long history of collaboration and a track record of launching dozens of early-stage life science ventures, and the firm is known for its deep technical expertise and active, founder-friendly mentorship. With offices in San Francisco and Cambridge, Massachusetts, Mission BioCapital operates in regions rich in research, discovery, and venture activity. The firm offers programs such as the Platinum Program, which provides up to $500,000 in funding, lab space, mentorship, and access to drug discovery, legal, and financial services. It collaborates with corporate and strategic partners to accelerate development and help translate scientific discoveries into therapies, including relationships with AbbVie and Ono Venture Investment. Founded in 2009, Mission BioCapital focuses on early-stage life sciences and biotechnology companies and emphasizes collaboration, innovation, and support for founders to address unmet medical needs.

Commodore Capital is a New York City-based venture capital firm focused on biopharmaceuticals. Founded in 2019, it seeks to invest in innovative companies developing new medicines and to support them through the early stages of a major innovation cycle in biopharmaceuticals. The firm emphasizes backing ventures driven by genetic and cellular therapy advances from smaller firms, aiming to help bring treatments to patients worldwide. It operates as a registered investment adviser and acts as a collaborative partner to portfolio companies throughout development and commercialization.

Kurma Partners is a Paris-based investment firm focused on financing innovation in healthcare and biotechnology across Europe. Founded in 2009, it operates as a management company that backs companies from early creation to development and expansion, often collaborating with leading academic research institutions and hospitals to translate discoveries into medicines and medical devices. The firm manages funds targeting life sciences, pharmaceuticals, biotechnology, digital health and related technologies, supporting European early-stage and growth-stage ventures through strategic partnerships and long-term value creation.

MPM BioImpact is a venture capital firm based in Boston that invests in biotechnology, healthcare, and life sciences companies across the entire drug development process, from early research to public markets. With over 30 years of experience, the firm backs private and public companies aiming to translate scientific breakthroughs into life-saving medicines. It emphasizes building and supporting ventures that improve patient outcomes, drawing on a team of industry experts and entrepreneur partners. Its portfolio includes Orna Therapeutics, developing circular RNA medicines, Aktis Oncology, pioneering radio-pharmaceuticals, and Reunion Neuroscience, advancing psychedelic-inspired therapies for mental health. MPM BioImpact has demonstrated a track record of backing companies that produce FDA-approved drugs, engage in M&A activity, and pursue initial public offerings, reflecting a continued commitment to advancing innovative therapies.

BioVenture is a China-based healthcare investment firm anchored in Suzhou's bioBAY ecosystem, specializing in early- and growth-stage life sciences companies. Since 2013, it has supported more than 200 portfolio companies across new drug discovery, medical devices, diagnostics, precision medicine and medical services, with a network built on BioBAY that enables post-investment value-add and rapid growth. The company is known for a seasoned investment team, strong industry resources, and world-class scientific advisors, and has backed multiple portfolio companies that have progressed to public listings on major markets. BioVenture emphasizes global reach, robust deal flow, and a commitment to helping portfolio companies scale through strategic guidance and operational support.

5AM Ventures is a San Francisco-based venture capital firm focused on seed- and early-stage investments in life sciences, healthcare, and related technologies. Founded in 2002 by John Diekman and Andrew Schwab, the firm backs private companies in biopharmaceuticals, drug delivery, medical technology, and life science instruments, predominantly in the United States and Canada. It operates from San Francisco with an additional Boston office, providing capital and hands-on support to advance breakthrough science and therapies and to translate scientific advances into clinical and commercial value.

Casdin Capital is a New York-based venture capital firm founded in 2012 by Eli Casdin. The firm focuses on life sciences and healthcare, including biotechnology, oncology, digital health, agtech, and related areas, and invests in private companies across stages from early to late, seeking opportunities that leverage data analysis, genomics, and precision medicine. It emphasizes partnerships with experienced teams and maintains a long-term investment horizon, and applies its data expertise to inform investment decisions while upholding ethical considerations in the industry.

VenBio is a venture capital firm focused on life sciences investing in U.S. based medical and biotechnology companies across early to late stages. The firm leads investments, builds syndicates, and works closely with portfolio teams to advance therapeutics from discovery through clinical development. Its approach emphasizes strong intellectual property, chemistry, manufacturing, and regulatory readiness, and it actively considers potential acquisition partners from the outset to maximize portfolio value. VenBio supports teams through development milestones, aiming to position companies for licensing or acquisition, and has a track record of backing ventures that have delivered FDA-approved drugs. The firm has offices in San Francisco and Seattle and manages nearly $2 billion in committed capital. The firm seeks to partner with industry leaders to address unmet medical needs and create meaningful patient impact.

Merck is a global, research-intensive biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing innovative medicines and vaccines. It pursues therapies across oncology, vaccines, infectious diseases, cardiometabolic and respiratory diseases, immunology, neuroscience, and ophthalmology, leveraging data science and artificial intelligence to advance drug development. Its immuno-oncology portfolio, including Keytruda, is a major contributor to sales, and its vaccines business, including Gardasil, targets pediatric diseases. The company emphasizes patient access through assistance programs and sustainability initiatives such as Merck for Mothers. With a long history and a global footprint, Merck focuses on scientific breakthroughs and aims to address unmet medical needs worldwide.

Aisling Capital is a New York-based venture capital firm that focuses on healthcare and life sciences. It backs mid- to late-stage and growth opportunities in pharmaceuticals, biotechnology, and related health technologies across North America and Europe, providing capital and strategic support to advance research, development, and commercialization of new therapeutics and medical products. With a history dating to 2000, the firm leverages deep industry experience to help companies address unmet medical needs and scale innovative therapies and services from discovery to market.

Takeda is a leading global biopharmaceutical company headquartered in Japan that researches, develops, manufactures, and markets prescription medicines and nutritional products. Its core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for a large share of revenue. The company maintains a broad geographic footprint with activity in the United States, Europe, Japan, and Canada, supported by an integrated research, development, manufacturing, and commercialization network. Takeda emphasizes innovation to improve patient outcomes through scientific discovery, strategic collaborations, and expanded access to medicines, while upholding strong governance and corporate responsibility.

The Column Group is a San Francisco-based venture capital firm focused on creating the next generation of biotechnology companies. It backs life sciences startups in drug discovery, oncology, and related technologies across the United States, supporting them from early discovery through development and potential commercialization with a long-term investment approach rather than short-term exits. The firm emphasizes rigorous scientific principles, hands-on mentoring of CEOs, and building strong, scientifically driven teams. It manages more than $4 billion in assets and operates multiple funds and platforms to support portfolio companies, including early-stage discovery through later-stage opportunities. Over its two-decade history, it has nurtured dozens of ventures and achieved multiple exits across biology, chemistry, and technology, reflecting a track record of accelerating breakthroughs in areas such as migraine treatment, cardiovascular disease, and cancer. The Column Group also runs leadership programs to foster biotech talent and maintains a focus on advancing science-led therapies in the U.S.

Ally Bridge Group is a global healthcare investment firm founded in 2013 with offices in New York and Hong Kong. It pursues venture, growth equity, private equity, and public market investments across the life sciences spectrum, including biopharmaceuticals, medical devices, and healthcare IT, aiming to back high-impact innovations that address unmet medical needs. The firm invests across the United States, China, and Europe, blending scientific and clinical expertise with capital markets know-how to support development and commercialization of breakthrough therapies and technologies, and to bridge healthcare innovations to global markets.

Venrock is a venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It concentrates on technology and healthcare, investing in seed and early-stage companies as well as growth opportunities, and has backed influential firms such as Apple Computer, Intel, Illumina, Nest, and SlideShare. The firm supports portfolio companies across information technology, life sciences, software, cybersecurity, and emerging technologies, pursuing disruptive innovations and long-term growth through partnerships with entrepreneurs to build enduring companies.

Abingworth is an international life sciences investment firm founded in 1973. It partners with life sciences entrepreneurs to translate scientific discoveries into therapies and diagnostics, investing across all development stages—from early-stage ventures to publicly traded companies—and across pharmaceutical, biotechnology, and related life science sectors. The firm maintains offices in London, Menlo Park, and Boston and provides portfolio companies with a dedicated team and strategic support. Throughout its history, Abingworth has backed numerous life science ventures and helped portfolio companies achieve IPOs and strategic mergers and acquisitions, reflecting its focus on delivering health impact through scientific innovation.

Pivotal bioVenture Partners is a San Francisco-based venture capital firm focused on early-stage life sciences and therapeutics companies. Founded in 2016, the firm invests across North America, Europe, and China in biotechnology, therapeutics, medical devices, and related life-science platforms addressing unmet medical needs. Its team combines venture investing with company-building and drug-discovery expertise to support entrepreneurs through early development and clinical milestones. The firm maintains a global footprint with offices in San Francisco, Shanghai, and Hong Kong, underscoring its cross-regional approach to health-care innovation. It has established multiple funds to back portfolio companies across cycles.

Third Rock Ventures is a Boston-based venture capital firm that concentrates on early-stage investments in life sciences and healthcare. It backs biotechnology, pharmaceuticals, medical devices, diagnostics, and related information technology companies with high growth potential, providing substantial initial capital and active support to accelerate development and commercial success. The firm emphasizes strategic collaborations and seeks meaningful involvement in portfolio companies, including potential leadership roles, to advance medicines, therapies, and diagnostics. By positioning its investments within the U.S. life sciences landscape, Third Rock Ventures aims to help startups translate scientific breakthroughs into clinically meaningful products and outcomes.

New Leaf Venture Partners is a New York-based venture capital firm that invests in healthcare technology companies. The firm backs companies across biopharmaceuticals, medical devices, information convergence, biological research tools, and life science infrastructure, providing strategic capital and operational insight to support growth. The team originated within Sprout Group, the healthcare technology practice of Credit Suisse First Boston, and spun out in 2005 to operate independently. New Leaf emphasizes long-term partnerships with entrepreneurs to advance innovative therapies, devices, and tools that aim to improve patient outcomes.

Longitude Capital is a California-based venture growth investment firm that concentrates on biotechnology, medical technology, and health solutions. Founded in 2006, it has raised over $1.2 billion across multiple funds and supports privately held and publicly traded life science companies. The firm emphasizes a balanced portfolio of clinically de-risked assets across clinical- and commercial-stage programs, pursuing attractive returns within three to five years of investment. It identifies opportunities through a broad network of industry relationships and thematic research into emerging therapeutic areas, and uses a range of investment structures including traditional venture financing, asset spin-outs, recapitalizations, PIPEs, open market purchases, royalties, and other equity-linked instruments. Longitude Capital aims to partner with portfolio companies to help them reach strategic objectives, with operations centered in Menlo Park, California.

IMM Investment is a Seoul-based asset manager and private equity/venture capital firm that engages in multi-asset investments across venture capital, growth equity, mezzanine, and infrastructure. The firm targets information technology, healthcare/biotech, manufacturing, and related high-growth sectors, and often takes an active management role to support portfolio companies. With offices in Seoul, Tokyo, and Hong Kong, it serves institutional investors and partners with innovative entrepreneurs through a diversified platform and cross-border strategies.

Pontifax Venture Capital is a Herzliya, Israel-based healthcare-focused venture capital firm that backs transformative life sciences companies worldwide, including pharmaceuticals, biotechnology, and medical devices. Founded in 2004, the firm provides capital and hands-on guidance across development stages, leveraging its industry network and operating experience to support strategic direction, capital markets access, and M&A activity for portfolio companies. Pontifax seeks to source innovative ideas globally and help build successful life sciences businesses through active partnerships and governance, with a focus on turning breakthrough concepts into clinically and commercially viable products.

Seventure Partners is a Paris-based venture capital firm founded in 1997 that focuses on digital technologies and life sciences. It pursues early to growth-stage investments across a broad portfolio including biotech, healthcare, nutrition, microbiome, medical devices and digital health, as well as technology sectors such as B2B software, fintech, retail tech, cybersecurity, IoT, and blue economy activities like sustainable aquaculture, biopolymers and recycling. The firm also backs sports, wellbeing and related digital solutions as part of its tech and life sciences scope. Seventure provides capital together with hands-on expertise, networks and operational support to help portfolio companies scale. With about one billion euros under management and offices in Paris with a global reach across Europe, North America, and Asia-Pacific, it backs entrepreneurs from early to growth stages and aims to accelerate growth and value creation for tomorrow's European leaders.

Lumira Ventures is a North American life sciences-focused venture capital firm with offices in Toronto, Boston, Montreal and Vancouver. It invests in biotechnology, biopharmaceuticals, medical devices, digital health and consumer health companies across Canada and the United States, supporting early to late-stage ventures. The firm partners with management teams to build innovative companies addressing significant unmet medical needs, aiming to maximize technology value through financings and active board participation. It assists portfolio companies in accessing capital, strategic partners and market channels to accelerate development and commercialization. With a portfolio of numerous active investee companies, Lumira Ventures draws on deep sector expertise to help companies advance therapies, diagnostics, devices and digital health solutions.

Based in Durham, North Carolina, Hatteras Venture Partners is a venture capital and private equity firm founded in 2000 that focuses on investing in biotech and healthcare companies in the United States. It targets venture and co-investment opportunities across the life sciences, including biopharmaceuticals, medical devices, diagnostics, healthcare IT, and healthtech, with a preference for early-stage and growth financings. The firm emphasizes a health-centric approach and active partnership, offering operational support such as talent recruitment, portfolio strategy, and hands-on guidance to help portfolio companies reach clinical and commercial milestones. With a national footprint and a history of building companies with patient impact, Hatteras leverages its experienced team and network to create value beyond capital.

Lux Capital is a venture capital firm founded in 2000 with offices in New York City and Silicon Valley. It invests in seed- and early-stage ventures, and in select later-stage opportunities, across science-driven sectors such as artificial intelligence, biotechnology, biochemistry, materials science, electronics, space, infrastructure, and aerospace, including areas like 3D printing, flying and surgical robotics, genomics, satellites, drones, and computational imaging. Lux backs technical founders and research-driven teams, providing capital alongside strategic input on product development, company building, and long-term positioning to translate scientific research into scalable businesses. The firm emphasizes opportunities grounded in underlying science, potential industry impact, and feasibility of execution over extended horizons, with an active approach to helping entrepreneurs build successful, high-growth companies. Lux manages approximately $4 billion in assets focused on seed, early-stage, and growth investments across the physical, material, and life sciences, and its investment team has built more than 20 companies from scratch.

Andreessen Horowitz is a venture capital firm founded in 2009 and headquartered in Menlo Park, California. It deploys capital across the full startup lifecycle, from seed to growth, and invests in a broad range of sectors including artificial intelligence, healthcare, consumer technology, fintech, cryptocurrency and blockchain, enterprise software, and infrastructure. The firm offers more than funding, providing an operating network that connects portfolio companies with technical advisors, executive talent, and industry operators to support growth and scale. Through its thought leadership and wide industry coverage, Andreessen Horowitz positions itself as a principal investor in technology-driven companies shaping software-enabled markets.